Monte Rosa Therapeutics, Inc.

NasdaqGS:GLUE 주식 리포트

시가총액: US$1.4b

Monte Rosa Therapeutics 경영진

경영진 기준 점검 3/4

Monte Rosa Therapeutics CEO는 Markus Warmuth, Jan2020 에 임명되었습니다 의 임기는 6.42 년입니다. 총 연간 보상은 $5.03M, 12.9% 급여 및 87.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $6.95M 가치에 해당하는 회사 주식의 0.48% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.4 년과 5.6 년입니다.

핵심 정보

Markus Warmuth

최고경영자

US$5.0m

총 보수

CEO 급여 비율12.92%
CEO 재임 기간6.4yrs
CEO 지분 보유율0.5%
경영진 평균 재임 기간2.4yrs
이사회 평균 재임 기간5.6yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Apr 21

What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today

One thing we could say about the analysts on Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) - they aren't optimistic...
분석 기사 • Feb 14

The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%

Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shares have retraced a considerable 26% in the last month, reversing a...
Seeking Alpha • Jan 08

Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation

Summary Monte Rosa Therapeutics delivered strong interim phase 1 results for MRT-8102, showing deep NEK7 degradation and competitive hsCRP reductions in cardiovascular risk patients. The results further validate its molecular glue degrader platform and position MRT-8102 as an upstream approach versus IL-1/IL-6 targeting biologics. Results of MRT-2359 in heavily pretreated patients with metastatic castration-resistant prostate cancer are inconclusive. This week's $200 million follow-on offering boosts pro forma cash to nearly $600 million, extending the runway and reducing the urgency to find a partner for MRT-8102. Read the full article on Seeking Alpha
분석 기사 • Dec 03

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shares have been powering on, with a gain...
분석 기사 • Oct 18

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Held Back By Insufficient Growth Even After Shares Climb 58%

Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shareholders have had their patience rewarded with a 58% share price jump...
분석 기사 • Jul 18

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth

Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shareholders have had their patience rewarded with a 29% share price jump...
분석 기사 • May 24

Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive

To the annoyance of some shareholders, Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shares are down a considerable 26...
분석 기사 • May 10

Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

It's been a mediocre week for Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shareholders, with the stock dropping 18...
Seeking Alpha • Mar 24

Monte Rosa Therapeutics: Exercise Extreme Caution

Summary Monte Rosa Therapeutics' stock dropped 17% after announcing MRT-2359's target shift to castration-resistant prostate cancer (CRPC) due to poor efficacy in lung and neuroendocrine cancers. The shift reduces MRT-2359's potential treatment population and commercial viability, entering a competitive CRPC market with established therapies. Concerns persist about MRT-2359's effectiveness in CRPC and potential financial strain if clinical readouts fail, risking the company's cash position and operations. Investors should remain cautious, as the stock may face continued downward pressure until more is known about MRT-2359's viability in CRPC trials. Read the full article on Seeking Alpha
분석 기사 • Feb 25

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 17

Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN

Summary One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partnerships with Roche and Novartis, which I think validate its technology to some extent, but have also given it non-dilutive funding. Currently, its pipeline has MRT‑2359, MRT‑6160, and MRT‑8102, with key data expected in 2025. GLUE’s platform basically unlocks previously “undruggable” targets. This may lead to many new potential treatment targets for diseases that are superior to currently available therapies. GLUE’s valuation still seems quite cheap relative to its potential. It’s trading near cash levels with ample runway, so I think it’s worth a “Buy” at these levels. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Monte Rosa Therapeutics: A First Assessment

Summary Monte Rosa Therapeutics' shares have surged after a recent $150 million partnership with Novartis, which helped validate its molecular glue degrader (MGD) approach despite limited clinical results. Monte Rosa focuses on MGDs for cancer and autoimmune diseases, with MRT-2359 in Phase 1/2 trials targeting MYC-driven tumors. The company now has significant collaborations with Roche and Novartis, providing substantial upfront payments and potential milestone revenues. Can the rally continue?  A first assessment around Monta Rosa Therapeutics is presented in the paragraphs below. Read the full article on Seeking Alpha
분석 기사 • Nov 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts

Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Oct 28

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash

Summary Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with potential $2.1 billion in milestone payments. Initial data from the phase 1 SAD/MAD study of MRT-6160 in healthy volunteers is expected in Q1 2025, potentially leading to mid-stage studies for UC and RA. MRT-2359 for MYC-driven solid tumors is also progressing, with phase 2 dose recommendations and updated results anticipated in the second half of 2024. The company had $267.1 million in cash as of June 30th of 2024; Enough to fund its operations into the 1st half of 2027. Read the full article on Seeking Alpha
분석 기사 • Sep 23

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
분석 기사 • Mar 20

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Sep 29

Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • May 01

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Jan 16

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Oct 01

We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO 보수 분석

Markus Warmuth의 보수는 Monte Rosa Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-US$130m

Dec 31 2025US$5mUS$650k

-US$39m

Sep 30 2025n/an/a

US$21m

Jun 30 2025n/an/a

US$24m

Mar 31 2025n/an/a

US$6m

Dec 31 2024US$2mUS$616k

-US$73m

Sep 30 2024n/an/a

-US$119m

Jun 30 2024n/an/a

-US$130m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$4mUS$616k

-US$135m

Sep 30 2023n/an/a

-US$133m

Jun 30 2023n/an/a

-US$125m

Mar 31 2023n/an/a

-US$117m

Dec 31 2022US$4mUS$582k

-US$109m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$94m

Mar 31 2022n/an/a

-US$86m

Dec 31 2021US$5mUS$525k

-US$74m

Sep 30 2021n/an/a

-US$70m

Jun 30 2021n/an/a

-US$57m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$2mUS$465k

-US$36m

보상 대 시장: Markus의 총 보수(USD5.03M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.30M) 수준입니다.

보상과 수익: Markus의 보상은 회사가 적자임에도 증가했습니다.

CEO

Markus Warmuth (55 yo)

6.4yrs
재임 기간
US$5,032,728
보수

Dr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc...

리더십 팀

이름직위재임 기간보수지분
Markus Warmuth
President6.4yrsUS$5.03m0.48%
$ 6.9m
Philip Nickson
Chief Business & Legal Officer4.3yrsUS$1.94m0%
$ 0
Filip Janku
Chief Medical Officer5yrsUS$1.94m0.0093%
$ 133.3k
Matthew Bowen
Corporate Controller & Principal Accounting Officerless than a year데이터 없음0.021%
$ 306.2k
Jennifer Champoux
Chief Operating Officer5.3yrs데이터 없음0.0058%
$ 82.9k
Magnus Walter
Chief Technology Officerless than a year데이터 없음데이터 없음
John Castle
Chief Data & Information Officer2.4yrs데이터 없음데이터 없음
Sharon Townson
Chief Scientific Officer2.1yrs데이터 없음0.0069%
$ 99.4k
Andrew Funderburk
Chief Investor Relations and Strategy Officer2.3yrs데이터 없음데이터 없음
2.4yrs
평균 재임 기간
52yo
평균 나이

경험이 풍부한 관리: GLUE의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.4 년).

이사회 구성원

이름직위재임 기간보수지분
Markus Warmuth
President6.4yrsUS$5.03m0.48%
$ 6.9m
Christine Siu
Independent Director5.5yrsUS$162.69k0%
$ 0
Andrew Schiff
Independent Chairman of the Board5.8yrsUS$186.85k0%
$ 0
Chandra Leo
Independent Director5.8yrs데이터 없음데이터 없음
Anthony Manning
Independent Director2.9yrsUS$159.77k0%
$ 0
Jan Skvarka
Independent Director3.3yrsUS$156.85k0%
$ 0
Owen Wallace
Scientific Advisor & Member of Scientific Advisory Board2.1yrsUS$1.42m데이터 없음
Kimberly Blackwell
Independent Director5.9yrsUS$162.69k0%
$ 0
Eric Hughes
Independent Director1.5yrsUS$150.60k0%
$ 0
Ali Behbahani
Independent Director6.2yrsUS$155.19k0%
$ 0
5.6yrs
평균 재임 기간
56.5yo
평균 나이

경험이 풍부한 이사회: GLUE의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.6 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/09 11:25
종가2026/06/09 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Monte Rosa Therapeutics, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Zhiqiang ShuBerenberg
Michael SchmidtGuggenheim Securities, LLC
Dingding ShiJefferies LLC